Management

Concert has built a dynamic management team with broad expertise in drug development and operational excellence.

• Roger Tung, Ph.D., President and CEO
• Nancy Stuart, Chief Operating Officer
• James Shipley, M.D., Chief Medical Officer
• Robert Silverman, J.D., Ph.D., Senior Vice President and General Counsel
• Robert Zelle, Ph.D., Vice President and Senior Fellow, Drug Development

Biographies of the Concert management team are available to download as a PDF.

Roger Tung, Ph.D., Co-Founder, President and CEO

Dr. Roger Tung is the scientific founder, President, and CEO of Concert Pharmaceuticals, which he co-founded in 2006. Before Concert, Roger worked in venture-backed start-up and major pharmaceutical companies; including Vertex Pharmaceuticals, as a founding scientist and most recently Vice President of Drug Discovery; Merck; and E.R. Squibb & Sons. At Vertex, he co-invented the marketed HIV protease inhibitors Lexiva® and Agenerase®, and oversaw the discovery of Incivek® and Kalydeco®, approved respectively to treat HCV infection and cystic fibrosis caused by the G551D CFTR mutation. Roger has published widely and been granted 60 U.S. patents. He received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich. Roger is a scientific advisor to public and private biotech companies and serves on the Board of Visitors of the University of Wisconsin-Madison School of Pharmacy.

[ back to top ]

Nancy Stuart, Chief Operating Officer

Ms. Nancy Stuart has over 20 years of biotechnology and pharmaceutical industry experience and currently serves as Chief Operating Officer of Concert Pharmaceuticals, Inc.  Prior to joining Concert in July 2006, she held senior level business and drug development positions at RRD International, Scion Pharmaceuticals, Kinetix/Amgen Inc., Vertex Pharmaceuticals, Inc. and Genzyme Corporation.  At Kinetix, Ms. Stuart established the business development strategy that culminated in its $170 million acquisition by Amgen.  At Vertex, she served as Vice President of Program Planning and Management and was responsible for Vertex’s strategic partnerships and global drug development programs. In addition, she co-directed the development of Agenerase®, Vertex’s HIV protease inhibitor and initiated the Thyrogen® program for thyroid cancer testing at Genzyme. She has had extensive experience in raising private capital for start up biotechnology companies. Ms. Stuart is a member of the Board of Directors for the YMCA of Greater Boston. She holds a Bachelor of Science from the University of Michigan, and an MBA from the Simmons College Graduate School of Management.

[ back to top ]

James Shipley, M.D., Chief Medical Officer

Dr. Shipley joined Concert Pharmaceuticals in January 2011 and currently serves as Chief Medical Officer. He has more than 15 years of industry experience including extensive knowledge in clinical operations and regulatory affairs.  Prior to joining Concert, he served as Senior Vice President of Clinical Development, Medical and Regulatory Affairs at Indevus Pharmaceuticals, which was subsequently acquired by Endo Pharmaceuticals.  While at Indevus he provided medical and scientific oversight and developed regulatory strategies for more than a dozen compounds in various stages of development. Before joining Indevus,
Dr. Shipley was Senior Vice President of Clinical Research at Praecis Pharmaceuticals, where he managed several clinical trials leading to a successful New Drug Application for a prostate cancer drug, as well as trials of compounds for Alzheimer's disease, non-Hodgkins lymphoma and pain indications.  Previously, he held several positions of increasing responsibility with Aventis Pharmaceuticals, most recently as Senior Director of CNS Clinical Research.  Prior to that, Dr. Shipley was an attending physician in the Mood Disorders program and Director of the Sleep Diagnostic and Research program at the University of Michigan.

[ back to top ]

Robert Silverman, J.D., Ph.D., Senior Vice President and General Counsel

Dr. Robert Silverman has over 20 years legal and scientific experience and currently serves as Senior Vice President and General Counsel of Concert Pharmaceuticals, Inc.  Prior to joining Concert in January 2007, he served as Associate General Counsel at Millennium Pharmaceuticals, Inc., where he was primarily responsible for developing and leading the company’s chemical patent practice. Prior to his tenure at Millennium, he was a senior patent attorney at Vertex Pharmaceuticals, Inc. where he played a major role in building its patent department.  Before Vertex, Dr. Silverman held positions of increasing responsibility in the law department of FMC Corporation where he became Group Patent Counsel overseeing intellectual property matters for multiple chemical businesses.  He was also a senior research chemist at FMC before joining its law department.  Dr. Silverman received his J.D. from Rutgers-Camden Law School.  He also has an undergraduate degree from Lehigh University, a Ph.D. in organic chemistry from the University of New Mexico and conducted postdoctoral research in chemistry at Stanford University.

[ back to top ]

Robert Zelle, Ph.D., Vice President and Senior Fellow, Drug Development

Dr. Robert Zelle has over 20 years of drug discovery and development experience and currently serves as Vice President and Senior Fellow, Drug Development of Concert Pharmaceuticals, Inc.  Prior to joining Concert in July 2006 he held key positions at Scion Pharmaceuticals, Acusphere, Vertex Pharmaceuticals and Abbott Laboratories.  Before Concert, Dr. Zelle founded Bell Rock Associates, a pharmaceutical development consulting firm.  He also served as Vice President of Chemistry at Scion where he was responsible for discovery chemistry, manufacturing, intellectual property and regulatory submissions.  Before Scion, he was Senior Director of Regulatory Affairs and Product Development at Acusphere.  In this role he was responsible for regulatory affairs, quality assurance, quality control and preclinical testing. Dr. Zelle has been granted 24 U.S. patents with numerous pending U.S. applications.  Dr. Zelle has had extensive experience filing investigational new drug (IND) applications and bringing compounds into clinical development.  He was an NIH postdoctoral fellow with Professor Samuel Danishefsky at Yale University.  He received his Ph.D. in organic chemistry at Indiana University from Professor Paul Grieco.

[ back to top ]